Famotidine Celebrex combination Does Not Reduce Time to Recovery or Mortality in Critically Ill Patients in the I-SPY COVID Trial

SAN FRANCISCO, Sept. 3, 2021.  Quantum Leap Healthcare Collaborative, the sponsor of the I-SPY COVID Trial, today announced that the Famotidine Celecoxib arm has been dropped from the trial due to futility, based on the low likelihood of...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials